SG11201804449WA - 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders - Google Patents
2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disordersInfo
- Publication number
- SG11201804449WA SG11201804449WA SG11201804449WA SG11201804449WA SG11201804449WA SG 11201804449W A SG11201804449W A SG 11201804449WA SG 11201804449W A SG11201804449W A SG 11201804449WA SG 11201804449W A SG11201804449W A SG 11201804449WA SG 11201804449W A SG11201804449W A SG 11201804449WA
- Authority
- SG
- Singapore
- Prior art keywords
- task
- treatment
- sleep
- phenyl
- pyridine derivatives
- Prior art date
Links
- XIKCPUYIKHDSKZ-UHFFFAOYSA-N 2-phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine Chemical class C=1C=CC=CC=1C=1N=C2C=CC=CN2C=1CN1CCNCC1 XIKCPUYIKHDSKZ-UHFFFAOYSA-N 0.000 title 1
- 230000029058 respiratory gaseous exchange Effects 0.000 title 1
- 206010040978 Sleep apnoeas Diseases 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical class C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010041235 Snoring Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15199270 | 2015-12-10 | ||
EP16196836 | 2016-11-02 | ||
PCT/EP2016/079973 WO2017097792A1 (de) | 2015-12-10 | 2016-12-07 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804449WA true SG11201804449WA (en) | 2018-06-28 |
Family
ID=57517877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804449WA SG11201804449WA (en) | 2015-12-10 | 2016-12-07 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
Country Status (26)
Country | Link |
---|---|
US (1) | US10759794B2 (ko) |
EP (1) | EP3386979B1 (ko) |
JP (1) | JP2018536693A (ko) |
KR (1) | KR20180088462A (ko) |
CN (1) | CN108290887A (ko) |
AU (1) | AU2016365676A1 (ko) |
BR (1) | BR112018011783A2 (ko) |
CA (1) | CA3007724C (ko) |
CL (1) | CL2018001511A1 (ko) |
CO (1) | CO2018005905A2 (ko) |
CU (1) | CU20180056A7 (ko) |
DO (1) | DOP2018000142A (ko) |
EA (1) | EA201891374A1 (ko) |
EC (1) | ECSP18043573A (ko) |
GE (1) | GEP20207104B (ko) |
HK (1) | HK1254853A1 (ko) |
IL (1) | IL259374A (ko) |
MX (1) | MX2018007040A (ko) |
NI (1) | NI201800066A (ko) |
PH (1) | PH12018501235A1 (ko) |
SG (1) | SG11201804449WA (ko) |
SV (1) | SV2018005704A (ko) |
TN (1) | TN2018000193A1 (ko) |
TW (1) | TW201734012A (ko) |
UY (1) | UY37013A (ko) |
WO (1) | WO2017097792A1 (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018011783A2 (pt) | 2015-12-10 | 2018-12-04 | Bayer Pharma Aktiengesellschaft | derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina, como bloqueadores dos canais de task-1 e task-2 para o tratamento de transtornos respiratórios relacionados ao sono |
WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
JOP20190141A1 (ar) * | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
BR112021007830A2 (pt) * | 2018-11-20 | 2021-08-03 | Bayer Aktiengesellschaft | antagonistas do adrenoceptor-alfa2 do subtipo c (al-fa-2c) para o tratamento da apneia do sono |
EA202191480A1 (ru) * | 2018-11-27 | 2021-08-27 | Байер Акциенгезельшафт | Способ получения фармацевтических лекарственных форм, содержащих ингибиторы task-1- и task-3-каналов, и их применение для терапии нарушений дыхания |
TW202108135A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合 |
US20220218700A1 (en) * | 2019-05-09 | 2022-07-14 | Bayer Aktiengesellschaft | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
IL292656A (en) | 2019-11-06 | 2022-07-01 | Bayer Ag | Adrenoreceptor adrac2 inhibitors |
WO2022008426A1 (en) * | 2020-07-06 | 2022-01-13 | Bayer Aktiengesellschaft | Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonist with a task1/3 channel blocker for the treatment of sleep apnea |
GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
AU2022418117A1 (en) | 2021-12-22 | 2024-07-11 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea |
MX2024007764A (es) | 2021-12-22 | 2024-07-04 | Bayer Ag | Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o. |
CN118785904A (zh) | 2021-12-22 | 2024-10-15 | 拜耳公司 | 用于治疗睡眠呼吸暂停的task1/3通道阻断剂与p2x3受体拮抗剂的结合物 |
MX2024008523A (es) | 2022-01-07 | 2024-07-19 | Bayer Ag | Antagonistas del adrenoceptor a2 subtipo c para el tratamiento de la apnea del sue?o. |
KR20240132345A (ko) | 2022-01-07 | 2024-09-03 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 2,3-디히드로벤조[b][1,4]디옥신-2-일메틸)피페라진-1-일 유도체 |
CN114507695B (zh) * | 2022-02-17 | 2023-09-19 | 四川大学华西医院 | 一种用于调控神经元活性的重组载体和方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
GB0017256D0 (en) | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
DE102006019589A1 (de) * | 2006-04-27 | 2007-10-31 | Sanofi-Aventis Deutschland Gmbh | Inhibitoren des TASK-1 und Task-3 Ionenkanals |
EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
AU2009249186B2 (en) | 2008-05-19 | 2014-05-22 | Sunovion Pharmaceuticals Inc. | Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators |
WO2011103715A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
NZ602311A (en) | 2010-03-18 | 2014-08-29 | Pasteur Institut Korea | Anti-infective compounds |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
WO2012004258A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
EP2671582B1 (en) | 2011-02-01 | 2016-07-13 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
CA2831356A1 (en) | 2011-03-31 | 2012-10-04 | Emblem Technology Transfer Gmbh | Imidazo [1,2-a]pyridine_compounds for use in therapy |
US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
EA023648B1 (ru) | 2011-09-12 | 2016-06-30 | Санофи | ИНДАНИЛЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРО-1H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ |
WO2013037914A1 (en) * | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
SG11201400092VA (en) | 2011-09-16 | 2014-07-30 | Sanofi Sa | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
PL2809669T3 (pl) | 2012-02-03 | 2017-07-31 | Sanofi | Skondensowane pirolodikarboksamidy i ich zastosowanie jako środki farmaceutyczne |
US20160120863A1 (en) * | 2013-05-24 | 2016-05-05 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
AU2015238537B2 (en) | 2014-03-26 | 2019-08-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
US9994570B2 (en) | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
WO2016085784A1 (en) | 2014-11-26 | 2016-06-02 | Merck Sharp & Dohme Corp. | Methyl diazepane orexin receptor antagonists |
JP2018012645A (ja) | 2014-11-26 | 2018-01-25 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
JP2018016544A (ja) | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ[2.2.2]オクタン誘導体 |
RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
BR112018011783A2 (pt) | 2015-12-10 | 2018-12-04 | Bayer Pharma Aktiengesellschaft | derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina, como bloqueadores dos canais de task-1 e task-2 para o tratamento de transtornos respiratórios relacionados ao sono |
JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
-
2016
- 2016-12-07 BR BR112018011783-8A patent/BR112018011783A2/pt not_active Application Discontinuation
- 2016-12-07 WO PCT/EP2016/079973 patent/WO2017097792A1/de active Application Filing
- 2016-12-07 AU AU2016365676A patent/AU2016365676A1/en not_active Abandoned
- 2016-12-07 SG SG11201804449WA patent/SG11201804449WA/en unknown
- 2016-12-07 EA EA201891374A patent/EA201891374A1/ru unknown
- 2016-12-07 US US15/756,867 patent/US10759794B2/en active Active
- 2016-12-07 CA CA3007724A patent/CA3007724C/en active Active
- 2016-12-07 TN TNP/2018/000193A patent/TN2018000193A1/en unknown
- 2016-12-07 EP EP16808613.0A patent/EP3386979B1/de active Active
- 2016-12-07 KR KR1020187019247A patent/KR20180088462A/ko unknown
- 2016-12-07 CN CN201680072084.7A patent/CN108290887A/zh active Pending
- 2016-12-07 MX MX2018007040A patent/MX2018007040A/es unknown
- 2016-12-07 JP JP2018530119A patent/JP2018536693A/ja active Pending
- 2016-12-07 GE GEAP201614824A patent/GEP20207104B/en unknown
- 2016-12-07 CU CUP2018000056A patent/CU20180056A7/es unknown
- 2016-12-08 TW TW105140561A patent/TW201734012A/zh unknown
- 2016-12-09 UY UY0001037013A patent/UY37013A/es not_active Application Discontinuation
-
2018
- 2018-05-15 IL IL259374A patent/IL259374A/en unknown
- 2018-06-06 CL CL2018001511A patent/CL2018001511A1/es unknown
- 2018-06-06 DO DO2018000142A patent/DOP2018000142A/es unknown
- 2018-06-07 SV SV2018005704A patent/SV2018005704A/es unknown
- 2018-06-08 CO CONC2018/0005905A patent/CO2018005905A2/es unknown
- 2018-06-08 NI NI201800066A patent/NI201800066A/es unknown
- 2018-06-08 EC ECIEPI201843573A patent/ECSP18043573A/es unknown
- 2018-06-08 PH PH12018501235A patent/PH12018501235A1/en unknown
- 2018-11-01 HK HK18113949.5A patent/HK1254853A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12018501235A1 (en) | 2019-02-04 |
HK1254853A1 (zh) | 2019-07-26 |
CN108290887A (zh) | 2018-07-17 |
GEAP202014824A (en) | 2020-01-27 |
CU20180056A7 (es) | 2018-10-04 |
UY37013A (es) | 2017-06-30 |
SV2018005704A (es) | 2018-09-10 |
CA3007724C (en) | 2023-10-17 |
US10759794B2 (en) | 2020-09-01 |
ECSP18043573A (es) | 2018-06-30 |
TW201734012A (zh) | 2017-10-01 |
EP3386979B1 (de) | 2020-07-29 |
GEP20207104B (en) | 2020-05-11 |
EA201891374A1 (ru) | 2018-11-30 |
DOP2018000142A (es) | 2018-06-30 |
TN2018000193A1 (en) | 2019-10-04 |
JP2018536693A (ja) | 2018-12-13 |
CL2018001511A1 (es) | 2018-09-21 |
EP3386979A1 (de) | 2018-10-17 |
AU2016365676A1 (en) | 2018-06-07 |
WO2017097792A1 (de) | 2017-06-15 |
BR112018011783A2 (pt) | 2018-12-04 |
MX2018007040A (es) | 2018-08-15 |
CO2018005905A2 (es) | 2018-07-10 |
NI201800066A (es) | 2019-03-14 |
KR20180088462A (ko) | 2018-08-03 |
IL259374A (en) | 2018-07-31 |
US20190062326A1 (en) | 2019-02-28 |
CA3007724A1 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804449WA (en) | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | |
PH12019502828A1 (en) | Diazabicylic substituted imidazopyrimides and their use for the treatment of breathing disorders | |
PH12019500131A1 (en) | Substituted diazahetero-bicyclic compounds and their use | |
TN2015000169A1 (en) | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
PH12019501408A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
JOP20190148A1 (ar) | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية | |
TN2016000121A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
EA201990341A1 (ru) | Замещенные диазагетеробициклические соединения и их применение |